The second arm is based around RNA processing and ALYREF/THOC4 (Fig 3B) and includes NPM1, DDX5 and CPSF6, which are all up-regulated in the three AML cell lines upon CBL0137 treatment. Here, ALYREF is linked to acute myeloid leukemia.